Harrow Inc
HROW
Market Cap$1.11B
Close$
$13.51
57.2% downside
Current Fair Value
57.2% downsideOvervalued by 57.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.11 Billion |
|---|---|
| Enterprise Value | $1.28 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.49 |
| Beta | 0.4 |
| Outstanding Shares | 35,826,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -50.05 |
|---|---|
| PEG | -161.08 |
| Price to Sales | 6.31 |
| Price to Book Ratio | 31.54 |
| Enterprise Value to Revenue | 5.99 |
| Enterprise Value to EBIT | 299.69 |
| Enterprise Value to Net Income | -59 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 4.08 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Harrow Health Inc
125 employeesHarrow Health, Inc. owns a portfolio of ophthalmic pharmaceutical businesses, including ImprimisRx, the nation's leading ophthalmology outsourcing facility and pharmaceutical compounding business. The company holds large equity positions...